

Abstract

The invention is intended to adapt an already established clinical procedure for the treatment of multiple sclerosis (MS) — the use of beta interferon — to treat chronic human spinal cord injury. The present invention relates to the prevention of chronic inflammation and demyelination following spinal cord injury.